SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction

By sjmartinez • October 29, 2023

Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang EH, Ky B, Lenihan D, Nohria A, Dani SS, Ganatra S. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC Heart Fail. 2023 Oct 12:S2213-1779(23)00596-6. doi: 10.1016/j.jchf.2023.08.026. Epub ahead of print. PMID: 37897456.

Tags: antineoplastic therapy, cardiomyopathy, Digestive Diseases, Outcomes, Publications, SGLT2 inhibitors

Statins in chronic liver disease: review of literature and future role

Pham N, Benhammou JN. Statins in chronic liver disease: review of literature and future role. Semin Liver Dis. 2024 May 3. doi: 10.1055/a-2319-0694. Epub ahead[...]

Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease

Brahmania M, Rogal S, Serper M, Patel A, Goldberg D, Mathur A, Wilder J, Vittorio J, Yeoman A, Rich NE, Lazo M, Kardashian A, Asrani[...]

Author Correction: Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer

Stackpole ML, Zeng W, Li S, Liu CC, Zhou Y, He S, Yeh A, Wang Z, Sun F, Li Q, Yuan Z, Yildirim A, Chen[...]